Impact of nutritional status on the prognosis of patients with metastatic hormone-naïve prostate cancer: a multicenter retrospective cohort study in Japan

Okamoto, Teppei; Narita, Shintaro; Takahashi, Masahiro; Sakurai, Toshihiko; Kawamura, Sadafumi; Hoshi, Senji; Ishida, Masanori; Kawaguchi, Toshiaki; Ishidoya, Shigeto; Shimoda, Jiro; Sato, Hiromi; Mitsuzuka, Koji; Tochigi, Tatsuo; Tsuchiya, Norihiko; Arai, Yoichi; Habuchi, Tomonori; Οhyama, Chikara

doi:10.1007/s00345-018-2590-2

Cited by 47 publications

(53 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 Among mHSPC patients, the prevalence of pretreatment anemia was as high as 44-50%. 5,16 This study showed that the prevalence of anemia in this entire cohort was 43%. Anemia in mHSPC patients may be attributed to several factors, including malnutrition and chronic in ammation.…”

Section: Discussionmentioning

confidence: 64%

Impact of Pretreatment Anemia on Upfront Abiraterone Acetate Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter Retrospective Study

Okamoto

Noro

Narita

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: Anemia has been a known prognostic factor in metastatic hormone-sensitive prostate cancer (mHSPC). We therefore examined the effect of anemia on the efficacy of upfront abiraterone acetate (ABI) in patients with mHSPC.Methods: We retrospectively evaluated 67 mHSPC patients with high tumor burden who received upfront ABI between 2018 and 2020 (upfront ABI group). We divided these patients into two groups: the anemia-ABI group (hemoglobin <13.0g/dL, n =21) and the non-anemia-ABI group (n =46). The primary objective was to examine the impact of anemia on the progression-free survival (PFS; clinical progression including death from any cause) of patients in the upfront ABI group. Secondary objectives included an evaluation of the prognostic significance of upfront ABI and a comparison with a historical cohort (135 mHSPC patients with high tumor burden who received androgen deprivation therapy (ADT/complete androgen blockade [CAB] group) between 2014 and 2019).Results: We found that the anemia-ABI group had a significantly shorter PFS than the non-anemia-ABI group. A multivariate Cox regression analysis showed that anemia was an independent prognostic factor of PFS in the upfront ABI group (hazard ratio, 5.08; P =0.007). Patients in the non-anemia-ABI group were determined to have a significantly longer PFS than those in the non-anemia-ADT/CAB group (n =69) (P =0.002). However, no significant difference was observed in the PFS between patients in the anemia-ABI and the anemia-ADT/CAB groups (n =66). Multivariate analyses showed that upfront ABI could significantly prolong the PFS of patients without anemia (HR, 0.17; P = 0.003), whereas ABI did not prolong the PFS of patients with anemia.Conclusion: Pretreatment anemia was a prognostic factor among mHSPC patients who received upfront ABI. Although the upfront ABI significantly improved the PFS of mHSPC patients without anemia, its efficacy in patients with anemia might be limited.

show abstract

Section: Discussionmentioning

confidence: 64%

Impact of Pretreatment Anemia on Upfront Abiraterone Acetate Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter Retrospective Study

Okamoto

Noro

Narita

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies have highlighted the usefulness of the GNRI when assessing how physically fit elderly patients are who have chronic diseases [11]. Recent studies have assessed the usefulness of the GNRI in patients with various cancers, including those of the lung, pancreas, head and neck, and gastrointestinal organs [7,[13][14][15][16][17][18]. In this study, we evaluated the potential of three immunonutritional parameters as prognostic factors for second-line PEM treatment in patients with mUC.…”

Section: Discussionmentioning

confidence: 99%

“…3 [1][2][3][4][5][6] vs. 6 [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] in the low-GNRI vs. high-GNRI group). In addition, the median CSS with second-line PEM therapy was 3.6 months (95% confidence interval [CI]: 2.5-6.1) and 11.8 months (95% CI: 6.2-NA) for the low-GNRI and the high-GNRI group, respectively (Fig.…”

Section: Patients' Characteristics and Tumor Responsementioning

confidence: 91%

See 1 more Smart Citation

Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis

et al. 2020

View full text Add to dashboard Cite

Background: We evaluated the prognostic efficacy of the Geriatric Nutritional Risk Index (GNRI) in second-line pembrolizumab (PEM) therapy for patients with metastatic urothelial carcinoma (mUC). Patients and Methods: From January 2018 to October 2019, 52 mUC patients, treated previously with platinum-based chemotherapy, underwent second-line PEM therapy. Peripheral blood parameters were measured at the start of treatment: serum neutrophil-to-lymphocyte ratio (NLR), serum albumin, serum C-reactive protein (CRP), and body height and weight. PEM was intravenously administered (200 mg every 3 weeks). The patients were organized into two groups based on their GNRI (<92 [low GNRI] and ≥92 [high GNRI]), and the data were retrospectively analyzed. Adverse events (AEs) were evaluated and imaging studies assessed for all patients. Analyses of survival and recurrence were performed using Kaplan-Meier curves. Potential prognostic factors affecting cancer-specific survival (CSS) were assessed by univariate and multivariate Cox regression analyses. Results: patients’ baseline characteristics, except for their BMI and objective response rate, did not significantly differ between the two groups. The median total number of cycles of PEM therapy was significantly higher for the high-GNRI group (n [range]: 6 [2–20] vs. 3 [1–6]). The median CSS with second-line PEM therapy was 3.6 months (95% confidence interval [CI]: 2.5–6.1) and 11.8 months (95% CI: 6.2–NA) in the low-GNRI and the high-GNRI group (p < 0.01), respectively. Significant differences in CSS between the low- and high-CRP or -NRL groups were not found. Multivariate Cox proportional-hazards regression analysis revealed that a poor Eastern Cooperative Oncology Group performance status, visceral metastasis, and a low GNRI were significant prognostic factors for short CSS (95% CI: 1.62–6.10, HR: 3.14; 95% CI: 1.13–8.11, HR: 3.03; 95% CI: 1.32–8.02, HR: 3.25, respectively). Of the AEs, fatigue showed a significantly higher incidence in the low-GNRI group. Conclusions: For mUC patients receiving second-line PEM therapy, the GNRI is a useful predictive biomarker for survival outcome.

show abstract

“…Individuals with GNRI less than 92 were assigned to the malnutrition group, and those with GNRI more than 92 were assigned to the normal group with mild or no risk of malnutrition [21].…”

Section: Outcome Measurementsmentioning

confidence: 99%

Association among Geriatric Nutrition Risk Index and functional prognosis in elderly patients with osteoporotic vertebral compression fractures: a retrospective cohort study

Nagai¹,

Uei²,

Nakanishi³

2020

Preprint

View full text Add to dashboard Cite

Background Osteoporotic vertebral compression fracture (OVCF) is one of the most common fractures in the elderly and the number is increasing. In addition, nutritional status is associated with functional prognosis in the elderly. However, there are limited reports on the relationship between nutritional status and functional prognosis in OVCF. Furthermore, there are no reports that have examined the relationship between OVCF nutritional status and functional prognosis using geriatric nutritional risk index (GNRI) for nutritional assessment. The aim of this study was to investigate the association between nutritional status, activities of daily living (ADL), and fall after fracture in patients with OVCF. Methods The clinical information of 187 conservatively treated OVCF patients was retrospectively examined. This information included: age, sex, body mass index, total number of drugs used for treatment at admission, bone mineral density, use of drugs for osteoporosis, fracture type, comorbidity severity, nutritional status, Barthel Index (BI), and fall after OVCF. Subjects were divided into two groups according to their GNRI. Propensity score matching was used to confirm factors affecting BI and falls after OVCF. Results Sixty-eight patients (36.4%) presented with malnutrition at fracture. According to multiple linear regression analysis, GNRI positively affected BI gain (β = 0.283, 95% confidence interval [CI], -122.2 to -0.706, p = 0.001). Furthermore, on logistic regression analysis, fall after OVCF was associated with GNRI (odds ratio = 0.896, 95% CI, 0.832 to 0.964, p = 0.003). Conclusions Malnutrition in elderly OVCF patients decreases the acquisition of ADL and increases fall risk. Improvement of nutritional status during OVCF treatment may lead to improvement of ADL and prevention of falls.

show abstract

Impact of nutritional status on the prognosis of patients with metastatic hormone-naïve prostate cancer: a multicenter retrospective cohort study in Japan

Cited by 47 publications

References 26 publications

Impact of Pretreatment Anemia on Upfront Abiraterone Acetate Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter Retrospective Study

Impact of Pretreatment Anemia on Upfront Abiraterone Acetate Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter Retrospective Study

Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis

Association among Geriatric Nutrition Risk Index and functional prognosis in elderly patients with osteoporotic vertebral compression fractures: a retrospective cohort study

Contact Info

Product

Resources

About